Trial Profile
A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2019
Price :
$35
*
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Postoperative infections; Staphylococcal infections
- Focus Adverse reactions
- 16 Oct 2019 According to a Destiny Pharma media release, results of this study were published in the peer reviewed Journal of Global Antimicrobial Resistance.
- 16 Oct 2019 Results presented in a Destiny Pharma media release.
- 05 Sep 2016 According to a Destiny Pharma media release, the company announced results from this study of of XF-73 for Decolonization of Staphylococcus Aureus.